Tune in today at 12:40 p.m. ET to watch our Founder and Chief Executive Officer, Rachel McMinn, in a fireside chat at the Stifel 2024 Healthcare Conference. A link to the webcast is available here: https://bit.ly/3YYq2ae
Neurogene Inc.
生物技术
New York，New York 14,493 位关注者
Reimagining the future for rare neurological diseases
关于我们
Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families. To do this, we are working with experts across the globe to advance a broad pipeline of programs to treat the underlying cause of serious neurological disorders and thereby address the overwhelming need for new therapies. Although the human genome was sequenced for the first time nearly 20 years ago, the true genomics revolution is taking place now, providing us with the ability to radically alter rare, genetic disorders. At Neurogene, we are working to provide medicines to improve the lives of neurologically-impaired and developmentally-delayed children and their families. We are building a team of passionate, driven individuals who envision a world in which all families have access to genetic medicines, even if the disorder is exceedingly rare. To learn more, please visit https://www.neurogene.com/careers/.
- 网站
-
https://www.neurogene.com
Neurogene Inc.的外部链接
- 所属行业
- 生物技术
- 规模
- 51-200 人
- 总部
- New York，New York
- 类型
- 私人持股
- 创立
- 2018
地点
-
主要
获取路线
535 W 24th St
5th Floor
US，New York，New York，10011
Neurogene Inc.员工
动态
-
Today, we reported third quarter 2024 financial results and highlighted recent updates. For full details and results, read today’s press release: https://bit.ly/4eEvFjI
-
-
We are pleased to announce positive interim efficacy data from the first four participants in the low-dose cohort of our ongoing Phase 1/2 trial of NGN-401 in female pediatric patients with Rett syndrome. These data support that NGN-401 has the potential to serve as a best-in-class gene therapy. ? To learn more about this update, attend our live webcast at 4:30 p.m. ET today. To join the webcast, visit the events and presentations section of our website here: https://bit.ly/48K4oek ? We will share an update of our registrational trial design in the first half of 2025 and additional interim efficacy data in the second half of 2025. ? Read today’s press release to learn more: https://bit.ly/40OulaG #GeneTherapy #RettSyndrome ?
-
-
Interim clinical data from our Phase 1/2 trial of NGN-401 for Rett syndrome will be featured during a late-breaker session at the 2024 Child Neurology Society Annual Meeting. Join our live webcast on November 11 at 4:30 p.m. ET for a review of the data! For more details, visit: https://bit.ly/3YtRgXk #CNSAM #GeneTherapy
-
-
Attending Cell & Gene’s 2024 Meeting on the Mesa? Don’t miss our Founder and Chief Executive Officer, Dr. Rachel McMinn, participate in a Science Slam focused on neurological disease. ? Alliance for Regenerative Medicine #MeetingontheMesa #cellandgene #CGMesa24 #GeneTherapy
-
-
Tune in today at 2:30 p.m. ET to watch our Founder and Chief Executive Officer, Dr. Rachel McMinn, in a fireside chat at the Cantor Global Healthcare Conference. A link to the webcast is available here: https://bit.ly/4g3hTsT #CantorHCC
-
-
Tune in today at 11:00 a.m. ET to watch our Founder and Chief Executive Officer, Dr. Rachel McMinn, in a fireside chat at the H.C. Wainwright & Co., LLC 26th Annual Global Investment Conference. A link to the webcast is available here: https://bit.ly/4dWYFDE #HCWainwrightGlobal
-
-
Today, we reported second quarter 2024 financial results and highlighted recent updates. For full details and results, read today’s press release: https://bit.ly/3YELJ0O ?
-
-
We are excited to announce that the?FDA has granted Regenerative Medicine Advanced Therapy #RMAT designation to NGN-401 for #RettSyndrome. ? RMAT designation is based on preliminary clinical evidence that a drug has the potential to address unmet medical needs. ? We look forward to continued collaboration with the FDA as we continue advancing our mission to bring life-changing medicines to those who are impacted by rare neurological diseases. ? #RMAT #Genetherapy #RettSyndrome ? To learn more, read today’s press release: https://bit.ly/3T2HyZ9
-
-
?? Neurogene Inc is on a mission: to improve the lives of patients and families devastated by rare neurological diseases. ?? The medicine Neurogene Inc. is creating has the potential to fundamentally change the way these disorders are treated. ?? We are so proud to be your partner $NGNE! Thrilled to welcome you to ring the Nasdaq Opening Bell! #NasdaqListed
-